The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Drug Pricing Bills Move Forward

Drug Pricing Bills Move Forward

September 20, 2019 • By Angus Worthing, MD, FACP, FACR

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You may have noticed a flurry of proposals coming out of Washington, D.C., aimed at reducing drug prices and patients’ out-of-pocket drug costs.

You Might Also Like
  • Drug Makers Met with Trump to Argue against Senate Pricing Bill
  • U.S. Senators Tell Drug Company Execs Pricing Is Morally Repugnant
  • U.S. Lawmaker Launches Investigation into Pharma Drug Pricing
Also By This Author
  • ACR Pushes for Patient Interests, Against Spending Cuts

In July, the Senate Finance Committee voted narrowly in favor of penalizing drug companies whose prices outpace inflation; if enacted, that bill would also increase reimbursement for biosimilars to average sales price (ASP) plus 8% (from +6, pre-sequester). It would also modify how ASP is determined by recalculating it to a lower number based on co-pay coupons used in the commercial market, which is potentially very concerning for infusion providers. The ACR has communicated this concern to the Senate. Finally, this bill would cap patients’ out-of-pocket costs for Medicare Part D.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A second Senate bill, still in committee, would revamp the pharmacy benefit manager (PBM) payment system, which is widely known to motivate price hikes, by requiring PBMs to pass 100% of rebates through to plans rather than splitting the rebate with the pharmaceutical company.

This week, the House of Representatives released a long-anticipated plan led by Speaker Nancy Pelosi (D-CA) that is more extensive than the Senate plans. It contains provisions to reduce U.S. drug prices according to an international price index. This mirrors the idea floated this past fall by the Trump administration, but with two key differences for rheumatologists: no vendor model and no flat fee for Part B drugs. Thus, doctors would remain able to provide buy-and-bill services to patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Instead of relying on vendors to contract at lower rates, the House plan would impose a high, escalating tax on companies that fail to meet the price target. It would also require manufacturers that have increased prices faster than inflation to either lower prices to 2016 levels or pay back the extra cost above inflation since 2016. Similar to the Senate bill, this plan would also cap out-of-pocket costs for patients in Part D.

In addition to these legislative plans, the Trump administration has promised to release a plan soon that would reduce drug prices according to some type of international pricing model. The White House is pushing agencies to increase transparency in the drug pricing system.

What will emerge from this drug pricing debate? Stay tuned. During the 2019 Advocates for Arthritis fly-in event, the ACR took the opportunity to highlight for Congress our drug pricing principles:

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  • Protect patient access to treatment;
  • Reduce and streamline utilization management, such as step therapy;
  • Provide access to drugs given in monitored settings;
  • Promote use of guidelines; and
  • Support safe, effective biosimilars.

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: drug pricing, Legislation

You Might Also Like:
  • Drug Makers Met with Trump to Argue against Senate Pricing Bill
  • U.S. Senators Tell Drug Company Execs Pricing Is Morally Repugnant
  • U.S. Lawmaker Launches Investigation into Pharma Drug Pricing
  • WHO Drug Pricing Talks May Fail to End Secrecy, Activists Fear

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)